Start free

Amylyx Pharmaceuticals, Inc. (AMLX) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 12, 2026.

Filings shown
22
Open-market buys
1
Open-market sells
21
Buys, 10b5-1 box not checked
1 of 1

Counts cover the 22 most recent Form 4 filings Tradune holds for AMLX (filed May 26 – Nov 12, 2026); the score below covers only the trailing 90 days (0 buys, 19 sells). SEC EDGAR Form 4 filings for AMLX last checked Nov 22, 2026, 09:00 UTC; the latest AMLX filing Tradune holds was filed Nov 12, 2026. This is not guaranteed to be the complete record — see AMLX's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 10 filings Tradune holds for AMLX filed Sep 2 – Nov 12, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

19 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
9 sales· 270,000 sh
checkbox disclosed
On filings with the box not checked
10 sales· 91,302 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
James M. FratesChief Financial Officer 0 6 — 50,810 −$1,557,563
Joshua B. CohenCo-Chief Executive Officer 0 4 — 130,464 −$3,964,182
Justin B. KleeCo-Chief Executive Officer 0 4 — 130,464 −$3,964,102
Camille L. BedrosianChief Medical Officer 0 2 — 10,028 −$324,868
Gina MazzarielloChief Legal Officer 0 2 — 9,536 −$309,506
George M. Milne Jr.Director 0 1 — 30,000 −$830,904

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

0/ 100

Net insider sales
0 distinct buyers0 buy · 19 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at AMLX

Insiders reported 1 open-market purchase of AMLX between May 26, 2026 and Nov 12, 2026, across 1 distinct buyer. The most recent purchase was reported by Karen Firestone (Director) on May 21, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

James M. Frates Chief Financial Officer · filed Nov 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 20,000 $6.88 253,625 +8.6% Nov 10, 2026
Option exercise Stock Option (right to buy) 20,000 — — — Nov 10, 2026
Open-market sale 10b5-1 box checked 7,200 $30.97 233,625 −3.0% Nov 10, 2026
Open-market sale 10b5-1 box checked 12,800 $30.32 240,825 −5.0% Nov 10, 2026
Option exercise Stock Option (right to buy) 20,000 — — — Nov 9, 2026
Option exercise 20,000 $6.88 253,625 +8.6% Nov 9, 2026
Open-market sale 10b5-1 box checked 7,700 $29.39 245,925 −3.0% Nov 9, 2026
Open-market sale 10b5-1 box checked 12,300 $30.11 233,625 −5.0% Nov 9, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Justin B. Klee Co-Chief Executive Officer · filed Nov 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 37,483 $29.39 3,575,573 −1.0% Nov 9, 2026
Open-market sale 10b5-1 box checked 62,517 $30.11 3,513,056 −1.7% Nov 9, 2026
Joshua B. Cohen Co-Chief Executive Officer · filed Nov 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 38,105 $29.39 3,575,018 −1.1% Nov 9, 2026
Open-market sale 10b5-1 box checked 61,895 $30.11 3,513,123 −1.7% Nov 9, 2026
George M. Milne Jr. Director · filed Oct 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 30,000 $27.70 782,881 −3.7% Oct 5, 2026
Camille L. Bedrosian Chief Medical Officer · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 7,947 $32.21 280,145 −2.8% Sep 10, 2026
Open-market sale 10b5-1 box not checked 2,081 $33.09 278,064 −0.7% Sep 10, 2026
James M. Frates Chief Financial Officer · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,042 $33.23 233,625 −0.4% Sep 10, 2026
Open-market sale 10b5-1 box not checked 9,768 $32.27 234,667 −4.0% Sep 10, 2026
Gina Mazzariello Chief Legal Officer · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 11 $33.34 190,838 −0.0% Sep 10, 2026
Open-market sale 10b5-1 box not checked 9,525 $32.46 190,849 −4.8% Sep 10, 2026
Joshua B. Cohen Co-Chief Executive Officer · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 919 $33.15 3,613,123 −0.0% Sep 10, 2026
Open-market sale 10b5-1 box not checked 29,545 $32.16 3,614,042 −0.8% Sep 10, 2026
Justin B. Klee Co-Chief Executive Officer · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,439 $33.16 3,613,056 −0.0% Sep 10, 2026
Open-market sale 10b5-1 box not checked 29,025 $32.13 3,614,495 −0.8% Sep 10, 2026
Karen Firestone Director · filed Sep 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 25,000 $1.76 91,900 +37% Aug 31, 2026
Option exercise 25,000 $5.05 116,900 +27% Aug 31, 2026
Option exercise Stock Option (right to buy) 25,000 — — — Aug 31, 2026
Option exercise Stock Option (right to buy) 25,000 — — — Aug 31, 2026
James M. Frates Chief Financial Officer · filed Aug 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 22,807 — 244,435 +10% Aug 18, 2026
Justin B. Klee Co-Chief Executive Officer · filed Aug 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 60,039 — 3,643,520 +1.7% Aug 18, 2026
Gina Mazzariello Chief Legal Officer · filed Aug 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 21,284 — 200,374 +12% Aug 18, 2026
Camille L. Bedrosian Chief Medical Officer · filed Aug 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 22,807 — 288,092 +8.6% Aug 18, 2026
Joshua B. Cohen Co-Chief Executive Officer · filed Aug 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 60,039 — 3,643,587 +1.7% Aug 18, 2026
Gina Mazzariello Chief Legal Officer · filed Jul 13, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 15,000 $17.61 179,090 −7.7% Jul 10, 2026
Open-market sale 10b5-1 box checked 15,000 $18.32 194,090 −7.2% Jul 9, 2026
Bernhardt G. Zeiher Director · filed Jun 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (right to buy) 24,372 — — — Jun 4, 2026
Karen Firestone Director · filed Jun 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (right to buy) 24,372 — — — Jun 4, 2026
Daphne Quimi Director · filed Jun 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (right to buy) 24,372 — — — Jun 4, 2026
George M. Milne Jr. Director · filed Jun 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (right to buy) 24,372 — — — Jun 4, 2026
Paul R. Fonteyne Director · filed Jun 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (right to buy) 24,372 — — — Jun 4, 2026
Karen Firestone Director · filed May 26, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 3,800 $13.51 66,900 +6.0% May 21, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to AMLX's (Nov 12, 2026).

Frequently asked about AMLX insider activity

How many insiders bought AMLX stock in these Form 4 filings?

1 distinct insider at Amylyx Pharmaceuticals, Inc. reported 1 open-market purchase (Form 4 code P) of AMLX shares between May 26, 2026 and Nov 12, 2026, the most recent filed by Karen Firestone (Director) on May 21, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for AMLX?

The most recent Form 4 on this page was filed by Joshua B. Cohen (Co-Chief Executive Officer) on Nov 12, 2026, reporting 2 transactions. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market AMLX insider sale shown?

The largest open-market sale among the filings shown was 62,517 AMLX shares at $30.11 (about $1,882,149) by Justin B. Klee (Co-Chief Executive Officer) on Nov 9, 2026. Value is shares × the price reported on the Form 4; that Form 4 has the Rule 10b5-1 box checked.

Do the recent AMLX insider purchases have the Form 4 10b5-1 box checked?

No. The one AMLX open-market purchase shown was reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Karen Firestone (Director) on May 21, 2026, 3,800 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for AMLX — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.